All In Biotech

Drug Trial Radar · NCT06631989

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Actual

Start

Sep 4, 2024

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Wayshine Biopharm, Inc.Industry
Sponsor type
Industry
First posted
Oct 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .

Conditions

  • EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

Interventions

  • WSD0922-FUDrug

    Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI Drug: WSD0922-FU Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR by IRCTime frame: every 6 weeks, up to 1 year
  2. PartA: To evaluate the safety of WSD0922-FU in patients with NSCLCTime frame: 8 months
  3. PartA: To evaluate the tolerability of WSD0922-FU in patients with NSCLCTime frame: 8 months
  4. PartA: To evaluate the Maximum Tolerated Dose (MTD) of WSD0922-FU in patients with NSCLCTime frame: 8 months
  5. PartA: Recommended Phase II Dose (RP2D) of WSD0922-FU in patients with NSCLCTime frame: 8 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • He'nan Cancer Hospital

    Zhengzhou, Henan, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • Sichuan Provincial Cancer Hospital

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.